UK’s MHRA expands approval for Merz TherapeuticsMerz Therapeutics’ XEOMIN
2023-06-08
上市批准
Preview
来源: Pharmaceutical Technology
Merz Therapeutics’ XEOMIN is injected intramuscularly to improve muscle tone. Credit: Mufid Majnun on Unsplash.
The UK’s medicines and healthcare products regulatory agency (MHRA) has granted approval for a new indication for Merz Therapeutics’ XEOMIN (incobotulinumtoxinA) to treat focal spasticity of the lower limbs affecting the ankle joint.
The therapy was previously approved in the UK to treat upper limb spasticity.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Carboxyamidotriazole Orotate in Glioblastoma Multiforme (GBM) GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Valbenazine Tosylate in Chorea GlobalData
View all
The expanded approval allows the company to provide holistic support to those living with spasticity who need comprehensive treatment.
The active ingredient in XEOMIN is incobotulinumtoxinA. It is injected intramuscularly to improve muscle tone.
The therapy blocks nerve impulses to the muscles to weaken voluntary muscle contraction. It relieves abnormal muscle tone by inhibiting the release of acetylcholine from the peripheral nerve endings.
Merz Therapeutics stated that XEOMIN can now be used to treat lower and upper limbs individually or simultaneously, by adjusting the dose as required.
Merz Therapeutics CEO Stefan König stated: “The label extension in the UK is an important step for Merz TherapeuticsMerz Therapeutics and the patients that we serve.
“With the UK becoming the second market, following Japan, to grant approval for the treatment of lower limb spasticity affecting the ankle joint, it establishes the UK as the pioneering European country in this area.”
The company noted that 400 units per injection is the maximum dose of XEOMIN required to treat lower limbs. 500 units is the maximum dose for the combined treatment of upper and lower limb spasticity.
XEOMIN has already received approval in more than 75 countries across the world for the treatment of blepharospasm, cervical dystonia, upper and lower limb spasticity and sialorrhea.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。